Regione Toscana

Azienda Ospedaliero Universitaria Careggi

UNIFI

Sindromi mielodisplastiche (MDS) Unit

Responsabile prof.ssa Valeria Santini

Professionisti coinvolti nel percorso di diagnosi e cura

  • anatomo-patologo
  • citogenetista e biologo molecolare
  • citofluorimetrista
  • trapiantologo
  • trasfusionista
  • cardiologo
  • geriatra
  • internista
  • infettivologo
  • radiologo

Questa Unit afferisce al Dipartimento Oncologico e di chirurgia ad indirizzo robotico e si occupa di diagnosi e cura delle sindromi mielodisplastiche (MDS), in ottica multidisciplinare, multiprofessionale e di rete che comprende le strutture di secondo livello AOUC, lo specialista territoriale, il MMG del paziente e, se previsto, l’ambito territoriale dell’Area Vasta.

Funzioni

  • organizzare l’assistenza al paziente migliorando i servizi in una prospettiva multidisciplinare, attraverso un gruppo di professionisti costituito dai referenti per le discipline specialistiche coinvolte, favorendo il lavoro di squadra e l’integrazione tra le professionalità
  • assicurare il costante adeguamento dei modelli organizzativi, trasferendo nella pratica clinica le più aggiornate esperienze e competenze, finalizzate all’impiego delle risorse secondo criteri di efficacia, efficianza ed economicità
  • promuovere e verificare l’applicazione di protocolli e linee guida, anche relativi a terapie innovative
  • collaborare alla realizzazione di percorsi formativi
  • sviluppare specifici progetti nell’ambito della ricerca

Percorso

  1. visita, anamnesi e valutazione comorbidità del paziente e Comprhensive Geriatric Assessment (CGA), in collaborazione con geriatri e cardiolgi
  2. aspirato e biopsia osteomidollare con studio di funzioni d’organo, citogenetico e molecolare (ques’ultimo in casi selezionati), in collaborazione con anatomo-patologi
  3. proposta terapeutica previa valutazione con la Continuità assistenziale extraospedaliera, medici internisti e geriatri
  4. creazione di un percorso preferenziale con la Medicina trasfusionale
Ricerca

Ricerche traslazionali di ematologia sperimentale finanziati da enti pubblici e privati, italiani e internazionali:

  • Responsabile scientifico   locale   nel   Progetto   cofinanziamento  PRIN-  MIUR (coordinatore F.Mandelli) Secondi messaggeri nella maturazione ed apoptosi delle cellule di leucemia mieloide acuta. Possibile bersaglio terapeutico? 01/01/1998 – 01/01/1999
  • Responsabile scientifico   locale   nel   Progetto   cofinanziamento  PRIN-   MIUR (coordinatore G.Saglio) Ipermetilazione del DNA nella progressione di malattia e nel follow up della leucemia mieloide cronica. 01/01/1999 – 01/01/2001
  • Responsabile scientifico   locale   nel   Progetto   cofinanziamento  PRIN-   MIUR (coordinatore M. Baccarani) Ruolo dell’ipossia e dell’oncogene fes nel controllo della crescita e nella resistenza al trattamento nella leucemia mieloide cronica. 01/01/2001 – 01/01/2003
  • Responsabile scientifico locale nel Progetto cofinanziamento PRIN- MIUR (coordinatore G.Leone) Profilo molecolare delle alterazioni epigenetiche in mielodisplasie  ad  alto rischio:  azione  specifica  di  diversi  inibitori  delle  istone deacetilasi. 01/01/2005 – 01/01/2007
  • Principal investigator: Bando Salute Regione Toscana- MDS proteomics: clinical significance of modifications in protein expression in bone marrow CD34+ cells from MDS patients. 01/01/2009 – 01/01/2011
  • Principal  investigator:  Grant  Ente  Cassa  di  Risparmio  di  Firenze-  Analisi modificazioni funzionali e molecolari in cellule midollari mielodisplastiche prima e dopo trattamento con azacitidina. 01/01/2011 – 01/01/2013
  • Leukemia and Lymphoma Society (LLS) Translational Research grant TRP-6016-14 (collaboratore locale; coordinatore Dr Maria Figueroa). 01/01/2013 – 01/01/2015
  • Principal  investigator:  Grant  Ente  Cassa  di  Risparmio  di  Firenze-  Alterazioni molecolari nella risposta ad azacitidina in pazienti con sindrome mielodisplastica. 01/01/2013 – 01/01/2015
  • Principal  investigator:  AIRC  -Investigator  Grant  –  IG  2015  biennale-  Title: Mechanisms of resistance to hypomethylating agents in myelodysplastic syndromes. 01/01/2015
  • Coordinatore internazionale in qualità di uno dei tre key  opinion  leaders del WP-2  per   MDS   del   progetto   europeo   finanziato  da   EU:   “HARMONY European Network  of Excellence”. 2017
Pubblicazioni

  • Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, PA, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee K, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F. ITACA: A New Validated International Erythropoietic Stimulating Agent Response Score that Further Refines the Predictive Pwer Previous Scoring AmJ2017Jul 4.doi:[Epub ahead of print] PubMedPMID
  • Santini V, Allione B, Zini G, Gioia D, Lunghi M, PA, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel WahabO,Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrer D, Saglio G, Figueroa M, Levis A. Aphase II, Multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.186.[Epub ahead of print]PubMedPMID: 28607470
  • Valencia-Martinez A, Sanna A, Masala E, CE , Br A, Gozzini A, Santini V. Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplatic syndromes with single multilineage dysplasia Haematologica. 2017 May 18. pii: haematol 2017.166124. doi: 10.3324/haematol.2017.166124 [Epubaheadprint]PubMedPMID:28522578
  • Musto P, Maurillo L, Simeon V, PA, Finelli C, Balleari E, Ricc A, Rivellini F, CA, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, VMT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol. 2017 Jun; 177(5):741-750.doi:10.1111/bjh.14621. Epub 2017 Apr 17.PubMed PMID: 28419408
  • Park S, Hamel JF, TA, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, RGJ, Bernal T, Ramos, Calabuig M, Guerci-Bresler A, BD, CP, Cheze S, Wattel E, RC, Vey N, Gioia D, Ferrer D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis – Stimulating Agents. J Clin oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28. PubMedPMID: 28350519.
  • Della Porta MG, Jackson CH, Alessandrino EP, RM, Bacigalupo A, van Lint MT, Bernardi M, Allione B, BA, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, TE, VMT, Musto P, Onida F, IAP, Cerretti R, Grillo G, Molteni A, Pioltelli P, BL, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, BF, Cazz M, Rambaldi A. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with  myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017 Apr 7. doi:10.1038/leu.2017.88.[Epub ahead of print] PubMedPMID: 28321120.
  • Varaldo R, Raiola AM, Di Grazia C, Aquino S, Beltrami G, Bregante S, Cruciani F, Dominietto A, Ghiso A, Giannoni L, Gualandi F, Ibatici A, Lamparelli T, Marani C, Van Lint MT, Santini V, Bacigalupo A, Angelucci E. Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. Am J Hematol. 2017 Jun;92(6):E117-E119. doi: 10.1002/ajh.24725. Epub 2017 Apr 29. PubMedPMID: 28316085.
  • Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari  P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F,  Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D’Errigo MG, Bova I, Zini G, Latagliata R. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3. PubMedPMID: 28162984
  • Santini V. Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):462-469. Review. PubMedPMID: 27913517
  • Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk-non-del (5q) myelodysplastic syndromes  (MDD). Leuk Res. 2017 Jan;52:50-57. doi:10.1016/j.leukres.2016.11.008. Epub 2016 Nov 13. Review. PubMedPMID: 27883945
  • Negoro E, Radivoyevitch T, Polprasert  C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA,  Maciejewski JP. Molecular predictors of response in patients with myeloid neoplasms treated with lenadomide. Leukemia 2016 Dec;30(12):2405-2409. doi:10.1038/leu.2016.228 Epub 2016 Aug 18. PubMedPMID: 27560106;PubMedCentral PMCID:PMC5143200.
  • Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk-Non-del(5q) Myelodysplastic Syndromes and Ineligible of Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol 2016 Sep 1;34(25):2988-96. doi:10.1200/JCO.2015.66.0118. Epub 2016 Jun 27. PubMedPMID:27354480.
  • Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V. Design and rationale of theQUAZAR Lower-Risk MDS(AZA-MDS-003) trial:a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and Trombocytopenia. BMC Hematol 2016 May 3;16:12. doi: 10.1186/s12878-016-0049-5 eCollection 2016. PubMed PMID: 27148452; PubMedCentral PMCID:PMC4855808.
  • Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS. Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? Haematologica. 2016 Jul;101(7):e280-3.doi:10.3324/haematol.2016.142695. Epub 2016 Apr 7. PubMed PMID:27056923; PubMed Central PMCID:PMC5004472.
  • Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche  (FISMonlus),  and Düsseldorf MDS Registry. Myelodysplastic syndromes with single neutropenia  or thromboytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. Br J Haematol 2016 Dec;175(5):975-979. doi:10.1111/bjh.13902. Epub 2016 Jan 15. PubMedPMID: 26773632.
  • Guryanova OA, Lieu YK,Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, Martinez AB, Rivera SA, Durham BH, Rapaport F, Keller MD, Pandey S, Bastian L, Tovbin D, Weinstein AR, Teruya-Feldstein J, Abdel-Wahab O, Santini V, Mason CE, Melnick AM, Mukherjee S, Levine RL. Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358 Epub 2015 Dec 29. PubMedPMID: 26710888; PubMedCentral PMCID:PMC4856586.
  • Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dugherty S, Chan G, Giagunidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol 2015 Oct;2(10):e417-26.doi: 10.1016/S2352-3026(15)00149-0.Epub 2015Oct 1. PubMedPMID: 26686043.
  • Santini V. Anemia as the Main Manifestation Myelodysplastic Syndromes. Semin Hematol. 2015 Oct;52(4):348-56. doi: 10.1053/j.seminhematol. 2015.06.002. Epub 2015 Jun 30. Review. PubMedPMID: 26404446.
  • Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, Hofmann WK. Updated recommendations on the management gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome-Emphasis on optimized dosing schedules and new formulations. Leuk Res. 2015 Oct;39(10):1028-33. doi: 10.1016/j.leukres.2015.06.008. Epub 2015 Jun 20. Review. PubMedPMID: 26293555.
  • Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Mic JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, Poloni A, Lunghi M, Solary E, Abdel-Wahab O, Santini V, Figueroa ME. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015 May;125(5):1857-72. doi: 10.1172/JCI78752. Epub 2015 Mar 30. PubMedPMID:25822018; PubMed Central PMCID:PMC4611703.
  • Santini V, Fenaux P. Treatment myelodysplastic syndrome with thrombomimetic drugs. Semin Hematol. 2015 Jan;52(1):38-45. doi: 10.1053/j.seminhematol.2014.10.005. Epub 2014 Oct 31. Review. PubMedPMID: 25578418.
  • Santini V. Life after hypomethylating agents in myelodysplastic syndrome: new strategies. Curr Opin hematol. 2015 Mar;22(2):155-62.doi: 10.1097/MOH.0000000000000117. Review. PubMedPMID:25603477.
  • Santini V. On raising the “dust of blood”: from unrevealing thrombopoies is to treatment of thrombocytopenias with thrombomimetic drugs. Semin Hematol. 2015 Jan;52(1):1-3. doi: 10.1053/j.seminhematol.2014.10.008. Epub 2014 Oct 31. PubMed PMID: 25578412.
  • Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22. Review. PubMedPMID: 25444075.
  • Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact iron chelation therapy. BMJ Support Palliat Care. 2016Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9. PubMedPMID: 25204541.
  • Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol. 2014 Sep;25 Suppl 3:iii57-69. doi: 10.1093/annonc/mdu180. Epub 2014 Jul 25. PubMedPMID: 25185242.
  • Voso MT, Santini V, Fabiani E, Fianchi L, Criscuolo M, Falconi G, Guidi F, Hohaus S, Leone G. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014 Apr;99(4):613-9. doi: 10.3324/haematol.2013.099549. Review. PubMedPMID: 24688109; PubMedCentral PMCID:PMC3971070.
  • Santini V. [Identification of myelodysplastic syndromes patients]. Recenti ProgMed. 2014 Mar;105(3):127-31. doi: 10.1701/1434.15875. Italian. PubMedPMID: 24675456.
  • Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Cacci G, Molteni A, Vallisa D, Voso MT, Fenu S, Brin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. PubMedPMID: 24580147.
  • Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24. Review. PubMedPMID: 24529413.
  • Adès L, Santini V. Hypomethylating agents and chemotherapy in MDS. Best Pract Res Clin Haematol. 2013 Dec;26(4):411-9. doi: 10.1016/j.beha.2013.09.010. Epub 2013 Oct 7. Review. PubMedPMID: 24507817.
  • Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA. Absence of aberrant myeloid progenitors by flow cytometry is assosiated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Cytometry B Clin Cytom. 2014 May;86(3):207-15. doi: 10.1002/cyto.b.21160. Epub 2014 Jan 28. PubMedPMID: 24474614.
  • Seymour JF, Bennett JM, List AF, Mufti GJ, Gore SD, Fenaux P, Santini V, Hetzer J, Songer S, Skikne BS, Beach CL. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. Br J Haematol. 2014 Apr;165(1):49-56. doi: 10.1111/bjh.12723. Epub 2014 Jan 28. PubMedPMID: 24467613.
  • FenauxP,SeymourJF,SantiniV,SilvermanL,GoreS,ListA,SanzG,MuftiGJ,EsteyE,SwernAS,BeachCL,Hellstrom-LindbergE.ChallengesphaseIIItrialdesignfnoveltreatmentsindiseaseswithnostandardtreatment:the AZA-001myelodysplasiastudyLeukRes.2014Feb;38(2):258-62.doi: Epub2013OctPubMedPMID:
  • Buchi F, Masala E, Rossi A, Valencia A, Spinelli E, Sanna A,Gozzini A,  Santini V. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. Epigenetics. 2014 Mar;9(3):387-95. doi: 10.4161/epi.27322. Epub 2013 Dec 2. PubMedPMID: 24300456; PubMed Central PMCID: PMC4053457.
  • Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT, Kosmider O, Fontenary M, Gozzini A, Bosi A, Santini V. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6. PubMedPMID: 24192812; PubMed Central  PMCID: PMC3948159.
  • Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. PubMedPMID: 24072851.
  • Onida F, Barosi G, Leone G, Malcovati L, Morra E, Santini V, Specchia G, Tura S. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO grours. Haematologica. 2013 Sep;98(9):1344-52. doi: 10.3324/haematol.2013.084020. Review. PubMedPMID: 24006407; PubMed Central PMCID: PMC3762089.
  • Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: pathogenesis myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol. 2013 Nov;88(2):231-45. doi: 10.1016/j.critrevonc.2013.06.004. Epub 2013 Jul 7. Review. PubMedPMID: 23838480.
  • Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellström-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul;98(7):1067-72. doi: 10.3324/haematol.2012.074831. Epub  2013 Apr 12. PubMedPMID: 23585522; PubMed Central PMCID: PMC3696610.
  • Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C, Ades L, Santini V, Park S, Toma A, Fenaux P, Dreyfus F, Fontenary M, Kosmider O. A G polymorphism in the CRBN gene acts as a biomarker response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia. 2013  Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26. PubMedPMID: 23434730.
  • Swords R, Santini V. In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? Hematology Am Soc Hematol Educ Program. 2012;2012:74-5. doi: 10.1182/asheducation-2012.1.74. Review. PubMedPMID: 23233563.
  • Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program. 2012;2012:65-73. doi: 10.1182/asheducation-2012.1.65. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2013;2013:692. PubMedPMID: 23233562.
  • Breccia M, Fianchi L, Lunghi M, Gaidano G, Levis A, Finelli C, Santini V, Musto P, Mansueto G, Oliva EN, Leoni P, Spiriti MA, Hohaus S, Leone G, Alimena G, Voso MT. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. Leuk Lymphoma. 2013 Aug;54(8):1786-7. doi: 10.3109/10428194.2012.749406. Epub 2012 Dec 10. PubMed PMID: 23151268.
  • Santini V. Treatment low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins.Semin Hematol. 2012 Oct;49(4):295-303. doi: 10.1053/j.seminhematol.2012.09.003. Review. PubMedPMID: 23079059.
  • Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D’Alò F, Hohaus S, Pagano L, Leone G, Voso MT. Outcome therapy-related myeloid neoplasms treated with azacitidine. J Hematol oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44. PubMedPMID: 22853048; PubMed Central PMCID: PMC3419605.
  • Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25. PubMed PMID: 22762033; PubMed Central PMCID: PMC3384400.
  • Masala E, Valencia A, Buchi F, Nosi D, Spinelli E, Gozzini A, Sassolini F, Sanna A, Zecchi S, Bosi A, Santini V. Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myeldysplastic marrow cells.  Leuk Res. 2012 Oct;36(10):1290-5. doi: 10.1016/j.leukres.2012.05.023. Epub 2012 Jun 27. PubMedPMID: 22742816.
  • Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, Sassolini F, Valencia A, Bosi A, Santini V. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Cancer Res. 2012 Jun1;18(11):3079-89. doi: 10.1158/1078-0432.CCR-11-0686. Epub 2012 Apr 11. PubMedPMID: 22496271.
  • Buchi F, Spinelli E, Masala E, Gozzini A, Sanna A, Bosi A, Ferrari G, Santini V. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res. 2012 May;36(5):607-18. doi: 10.1016/j.leukres.2011.11.24. Epub 2012 Jan 9. PubMedPMID: 22230298.

Loading

Ultimo aggiornamento

18 Settembre 2023, 11:26

Skip to content